Skip to main content
SpringerLink
Log in

Radiotherapy for Localized and Locally Advanced Prostate Cancer

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Book cover Urologic Oncology

  • 151 Accesses

Abstract

Radiotherapeutic management encompasses all stages of prostate cancer. Conformal and intensity-modulated techniques have made possible dose-escalated external radiotherapy improving survival outcomes in localized disease and reducing toxicity in the postoperative adjuvant setting. Stereotactic techniques, under rigorous conditions, permit moderate and extreme hypofractionation which shortens the overall treatment time. In the curative setting, this can be a tool for dose escalation by taking advantage of the radiobiologic properties of prostate cancer. In the palliative setting, this allows for shorter regimens and, more importantly, re-irradiation. Finally, with the advent of transrectal ultrasonography, prostate brachytherapy has emerged as a versatile tool, either as a monotherapy in the treatment of low- or intermediate-risk disease, as a boost to external radiotherapy in high-risk disease, or as salvage treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abdel-Wahab M, et al. Second primary cancer after radiotherapy for prostate cancer—a SEER analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:58–68.

    Article  Google Scholar 

  • Alicikus ZA, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117:1429–37.

    Article  Google Scholar 

  • Al-Mamgani A, et al. Update of Dutch multicenter dose escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–8.

    Article  Google Scholar 

  • Aluwini S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16(3):274–83.

    Article  Google Scholar 

  • Arcangeli G, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79:1013–21.

    Article  Google Scholar 

  • Asbell SO, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys. 1988;15:1307.

    Article  CAS  Google Scholar 

  • Ash D, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57(3):315–21.

    Article  CAS  Google Scholar 

  • Beckendorf V, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.

    Article  Google Scholar 

  • Bolla M, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066.

    Article  CAS  Google Scholar 

  • Brenner DJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88(2):398–406.

    Article  CAS  Google Scholar 

  • Chen CP, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013;86(2):324–9.

    Article  Google Scholar 

  • Chung H. Focal salvage HDR brachytherapy for the treatment of prostate cancer (NCT01583920). 2016. Retrieved from clinicaltrials.gov: https://clinicaltrials.gov/show/NCT01583920

  • Chung H. Pilot study of whole gland salvage HDR prostate brachytherapy for locally recurrent prostate cancer (NCT02560181). 2016. Retrieved from clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02560181?term=prostate+salvage+brachytherapy&rank=3

  • Cox JD, et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.

    Article  CAS  Google Scholar 

  • D’Amico AV, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289.

    Article  Google Scholar 

  • Davis BJ, et al. American brachytherapy society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11:6–19.

    Article  Google Scholar 

  • Dearnaley DP, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–87.

    Article  Google Scholar 

  • Dearnaley DP, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15:464.

    Article  Google Scholar 

  • Denham JW, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12:451.

    Article  CAS  Google Scholar 

  • Gomez-Veiga F, et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int. 2012;109(s1):17–21.

    Article  Google Scholar 

  • Guerif S, et al. Focal salvage HDR brachytherapy for local prostate cancer recurrence after primary radiation therapy: early experience of prospective study. Brachytherapy. 2014;13:S116–7.

    Article  Google Scholar 

  • Hamdy FC, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.

    Google Scholar 

  • Heemsbergen WD, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110:104.

    Article  Google Scholar 

  • Hoskin PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217–22.

    Article  Google Scholar 

  • Hoskin PJ, et al. GEC/ESTRO recommendations on high dose rate afterloading. Radiol Oncol. 2013;107:325–32.

    Article  Google Scholar 

  • Hsu CC, et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(2):370–7.

    Article  Google Scholar 

  • Hu K, et al. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40:783–6.

    Article  CAS  Google Scholar 

  • James ND, et al. Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed non-metastatic prostate cancer: data from >690 patients in the control arm of the STAMPEDE trial. Int J Radiat Oncol Biol Phys. 2014;90:S13.

    Article  Google Scholar 

  • Jo Y, et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int. 2012;109(6):835–9.

    Article  Google Scholar 

  • King CR, et al. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104–11.

    Article  Google Scholar 

  • King CR, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiol Oncol. 2013;109:217–21.

    Article  Google Scholar 

  • Koontz BF, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68(4):683–91.

    Article  Google Scholar 

  • Kuban D, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol. 2008;70(1):67–74.

    Article  Google Scholar 

  • Kuban DA, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79:1310.

    Article  Google Scholar 

  • Kupelian PA, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol. 2004;58:25–33.

    Article  Google Scholar 

  • Lawton CA, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646.

    Article  Google Scholar 

  • Lee B, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67(4):1106–12.

    Article  Google Scholar 

  • Leibel SA, et al. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys. 1994;28:7.

    Article  CAS  Google Scholar 

  • Locke J, et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy. A prospective study. Int J Radiat Oncol Biol Phys. 2002;52(3):712–9.

    Article  Google Scholar 

  • Losa A, et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology. 2003;62:1068–72.

    Article  Google Scholar 

  • Marks LB, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.

    Article  Google Scholar 

  • Michalski J, et al. Clinical outcome of patients treated with 3D conformal radiation therapy 3D-CRT for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012a;83:e363–70.

    Article  Google Scholar 

  • Michalski JM, et al. Prostate cancer. In: Joel T, Gunderson LL, editors. Clinical radiation oncology 3e. Philadelphia: Elsevier Saunders; 2012b. p. 1070–1.

    Google Scholar 

  • Morris WJ, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2016;98(2):275–85.

    Article  Google Scholar 

  • Mottet N, et al. EAU – ESTRO – SIOG guidelines on prostate cancer. European Association of Urology; 2016.

    Google Scholar 

  • Nag SC. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2001;51:1422–30.

    Article  CAS  Google Scholar 

  • National Cancer Comprehensive Network. NCCN guidelines version 3.2016 prostate cancer. 2016.

    Google Scholar 

  • Niehoff P, et al. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy. 2005;4(2):141–5.

    Article  Google Scholar 

  • Peters M, et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol. 2014;112(1):77–82.

    Article  Google Scholar 

  • Peters M, et al. Urethral and bladder dosimetry of total and focal salvage iodine-125 prostate brachytherapy: late toxicity and dose constraints. Radiother Oncol. 2015;117(2):262–9.

    Article  Google Scholar 

  • Peters M, et al. Rectal dose constraints for salvage iodine-125 prostate brachytherapy. Brachytherapy. 2016;15(1):85–93.

    Article  Google Scholar 

  • Pilepich MV, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285.

    Article  CAS  Google Scholar 

  • Pommier P, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366.

    Article  Google Scholar 

  • Roach M, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585.

    Article  Google Scholar 

  • Robinson JW, et al. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:1063–8.

    Article  Google Scholar 

  • Tetreault-Laflamme A, et al. Options for salvage of radiation failures for. Semin Radiat Oncol. 2016;27:67–78.

    Article  Google Scholar 

  • Tharp M, et al. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy. 2008;7(3):231–6.

    Article  Google Scholar 

  • Traudt K, et al. Prostate cancer recurrence after radical prostatectomy. Urology. 2011;77:1416–9.

    Article  Google Scholar 

  • Wilkins A, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015;16:1605–16.

    Article  Google Scholar 

  • Yamada Y, et al. A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014;13(2):111–6.

    Article  Google Scholar 

  • Yeoh EE, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072–83.

    Article  Google Scholar 

  • Zelefsky MJ, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases free survival outcomes. Eur Urol. 2011;60:1133–9.

    Article  Google Scholar 

  • Zietman AL, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–9.

    Article  CAS  Google Scholar 

  • Zietman A, et al. A randomized trial comparing conventional-dose with conformal radiation therapy high-dose in early stage adenocarcinoma of the prostate. Long-term results from Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09. J Clin Oncol. 2010;28:1106–11.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Genito Urinary Unit, Gustave Roussy, Villejuif, France

    Alberto Bossi

  2. Department of Radiation Oncology, Gustave Roussy, Villejuif, France

    Warren R. Bacorro

  3. Departement of Radiation Oncology Genitourinary Unit, Henry MONDOR Hospital APHP, Creteil, France

    Gabriele Coraggio

  4. Brachytherapy Unit, Department of Radiation Oncology, University of Santo Tomas Hospital - Benavides Cancer Institute, Manila, Philippines

    Warren R. Bacorro

Authors
  1. Alberto Bossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Warren R. Bacorro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gabriele Coraggio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Bossi .

Editor information

Editors and Affiliations

  1. Urologie, Univ Lübeck, Lübeck, Schleswig-Holstein, Germany

    Axel Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Martini-Klinik am UKE GmbH, Hamburg, Germany

    Thomas Steuber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Bossi, A., Bacorro, W.R., Coraggio, G. (2019). Radiotherapy for Localized and Locally Advanced Prostate Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_74-3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_74-3

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Radiotherapy for Localized and Locally Advanced Prostate Cancer
    Published:
    08 November 2018

    DOI: https://doi.org/10.1007/978-3-319-42603-7_74-3

  2. Radiotherapy for Localized and Locally Advanced Prostate Cancer
    Published:
    30 October 2018

    DOI: https://doi.org/10.1007/978-3-319-42603-7_74-2

  3. Original

    Radiotherapy for Localized and Locally Advanced Prostate Cancer
    Published:
    14 August 2018

    DOI: https://doi.org/10.1007/978-3-319-42603-7_74-1

Search

Navigation